“Cure App Co., Ltd.”which conducts research and development for "Treatment Applications®" issued a third-party allocation of new shares to a total of about 1.5 billion yen


To the press and whom it may concern:

Cure App Co., Ltd.which conducts research and development for "Treatment Applications®" issued a third-party allocation of new shares to a total of about 1.5 billion yen


Cure App Co., Ltd. (Head office: Chuo , Tokyo. President and CEO: Kota Satake), which conducts research and development for medical treatment applications for the treatment of disorders, announced today that they are implementing a third-party allocation of new shares of over 1.5 billion yen with newly acquired investors: the ITOCHU Corporation, ITOCHU Technology Ventures, CYBERDYNE Corporation, Dai-ichi Life Insurance Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., Iwashin Business Creation Capital Co., Ltd., Saison Ventures Co., Ltd. (Credit Saison corporate Venture Capital), Chibagin Capital Corporation, Mizuho Capital Corporation in addition to our existing investors, Beyond Next Ventures and Keio Innovation Initiative.

【Background and Purpose · Our Objective】 
Cure App is a new form of medical treatment applied in conjunction with the evolution of mobile technology aiming to increase medical results by implementing individually optimized (personalized) medical care.

Specifically, it allows for intervention in areas that have up until now been difficult to control regarding patient awareness, customs, and time zones (including times when patients are away from the hospital, at home, going about their daily lives, etc.).We are planning to construct a mechanism to conciliate treatment through a medical application known as a "treatment application®︎" for a wide range of patients and their lifestyles by following appropriate time frames and measures that correspond to each patient's individual condition.

While discussions regarding the use of ICT, AI, etc. for medical care and nursing care in Japanese society are currently progressing, the new capital increases the affinity between the image of the future that the nation is aiming for, our company's business, projects for private corporations and the possibility of overseas expansion, were evaluated and implemented.



In the future our company aims to become Japan's first pharmaceutically approved / insured company in regards to a nicotine addiction treatment application.  This application is currently undergoing clinical trials with the aid of this fund. We will continue to conduct research on this "Treatment Application" as well as applications for other diseases.



We have also begun developing the "Mobile Health Program" for private corporations in order for the knowledge accumulated in the development of "Treatment Applications" to be used for health promotion in private corporations.
In addition to the currently available "Ascure Smoking Cessation Program", we are planning to develop programs for lifestyle diseases and mental health issues. Furthermore, as a mobile solution that has come from Japan, we are planning to expand into globally.


【About Cure App Co., Ltd.】
Cure-Up Co., Ltd. is a MedTech venture company that conducts R & D and manufacturing of medical treatment equipment programs for the treatment of diseases based on medical evidence and advanced software technology.

In order to achieve a new medical service in Japan for the first time, in which "an application has the effect of treating a disease", we are working on the development of a "treatment application®︎ ": An application for treating diseases.


The aim of a "treatment application®︎" is to create a new effective treatment through analysis and guidance provided by an application that uses medical knowledge and evidence based on the daily treatment course of each patient. It also has the possibility to contribute to the improvement of conditions by encouraging the development of habitual aspects of a patient by transforming their awareness and behavior. We have began clinical trials early in Japan, and have also begun developing applications for multiple diseases.

In addition, based on the models produced in Japan, we plan to proceed by expanding to "Global Health Solutions from Japan".


The development status of the current "treatment application" is as follows:  
  • An application for the treatment of nicotine addiction: Joint development with the respiratory department of medicine at the Keio University School of Medicine. Multicenter cooperative clinical trials began in February of 2015. Clinical trials began in October 2017. 
  • The Nonalcoholic steatohepatitis (NASH) treatment application: Collaborative research with a hospital affiliated university. Ongoing clinical studies have been in effect since October of 2016.

 "Treatment application®︎" is a registered trademark of Cure App Co., Ltd..


The current developmental status of the "Mobile health program for private corporations" is as follows: 
  • ascure smoking cessation program: the success rate of smoking cessation with "complete online x 6 month support" of applications and non-smoking instructors. We are aiming for the improvement of the new digital technology era health support program and ICT.While released in April 2017, it has already been introduced by many companies most of which are TSE companies.

【Overview of the Following】 

  • Beyond Next Ventures 
(Head Office: 1-4-3 Nihonbashi Honcho, Chuo, Tokyo. Representative Director: Takeshi ITO)

  • Keio Innovation · Initiative 
 (Head office: 1-4-28 Mita, Minato, Tokyo. Representative President: Kotaro Yamagishi)

  • ITOCHU CO., LTD. 
(Head Office:  2-5-1 Kita Aoyama, Minato, Tokyo. President Masahiro Okuto)

  • ITOCHU TECHNOLOGY VENTURES CO., LTD. 
(Head Office: 2-5-1, Kita Aoyama, Minato, Tokyo. President: Shinji Nakano)

  • CYBERDYNE CO., LTD.
 (Head Office: 2-2-1 Gakuen,Tsukuba, Ibaraki. President and Representative Director: Yoshiyuki Sankai)

  • Dai-ichi Life Insurance Co., Ltd. 
(Head Office: 1-13-1 Yuraku, Chiyoda, Tokyo. Representative Director: Shinji Inagaki)
  • Mitsubishi UFJ Capital Co., Ltd. 
(Head Office: 1-7-17 Nihonbashi, Chuo, Tokyo. President: Muneki Honda)

  • Iwakin Business Creation Capital Co., Ltd. 
(Head Office: 1-2-3 Chuodori, Morioka, Iwate. President and Representative Director: Hideyasu Inagaki)

  • Saison Co., Ltd. 
(Headquarters: 52 Sunshine 60, 3-1-1 Higashi Ikebukuro, Toshima, Tokyo. President: Yoshiaki Miura)

  • Chibagin Capital Co., Ltd. 
(Head Office: 1-10-2 Nakase, Mihama, Chiba. President and Representative Director: Hideaki Sasaki)

  • Mizuho Capital Corporation 
(Head Office: 1-2-1 Uchisaiwai, Chiyoda, Tokyo. Representative Director: Hajime Saito)


【Cure App Company Outline】 
Company name: CureApp, Inc. 
President: Kota Satake. 
Head office: Kodenmacho YS Building 4th Floor, 12-5, Kodenma, Nihonbashi, Chuo, Tokyo.  
Capital reserve: 1,966,500,000 yen
Established: July 31st, 2014. 
Business contents: Program Medical device development, PHR (personal health record) business, Mobile health related service business. 
Trademark registration: "Treatment application®︎" "CureApp®︎" "ascure®︎" "Prescription application®︎
URL: http: // cureapp.co.jp/

【For inquiries concerning this matter】 
Cure Up Co., Ltd. 
Public Relations Mishima 
support@cureapp.jp











Comments

  1. I would like to thank you for the efforts you have made in writing this article. I am hoping the same best work from you in the future as well. Thanks... medical care essay

    ReplyDelete

Post a Comment

Popular posts from this blog

World’s First Medical Device Regulatory Approval of Digital Therapeutic App for Hypertension

CureApp SC, Digital Therapeutic for Nicotine Addiction: Introducing a New Form of App-based Prescription Treatment Reimbursed in Japan’s Public Healthcare Insurance System

【Publication information】"Digital Therapeutics will Become a Major Treatment Option in the Future: Kohta Satake, CEO of CureApp."